The World's Only Transdermal Dopamin Agonist, Neupro® Patch, Approved in Japan for Both Parkinson's Disease and Restless Legs Syndrome The only transdermal dopamine agonist*1 system, which helps ...
Rotigotine 2 mg/24 hours, 4 mg/24 hours, 6 mg/24 hours; transdermal patch; contains sulfites. Neupro is a transdermal patch containing rotigotine, a D3/D2/D1 dopamine agonist. The mechanism of action ...
ATLANTA, Dec. 13 /PRNewswire/ -- UCB announced today that the supplemental New Drug Application (sNDA) for the use of Neupro(R) as a treatment for moderate-to-severe restless legs syndrome (RLS) has ...
Latest safety and efficacy results for rotigotine in the treatment of moderate to severe restless legs syndrome presented at major North American neurology congress Brussels (Belgium), 13 April 2010, ...
FDA Approves Schwarz Pharma's Neupro for the Treatment of Early-Stage Parkinson's Disease in the U.S. MONHEIM, Germany, May 10 -- SCHWARZ PHARMA announced today that the U.S. Food and Drug ...
Atlanta, April 13th, 2010 – New data presented at the 62nd American Academy of Neurology annual meeting in Toronto, Canada, showed that patients with moderate to severe Restless Legs Syndrome (RLS) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results